Twist, Cancer Research Horizons team to advance research on cancer

Twist Bioscience and Cancer Research Horizons announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries. “Teaming up with Cancer Research Horizons to support exploratory drug discovery efforts, validating and de-risking biological targets has the potential to be groundbreaking for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our ‘Library of Libraries.’ With two mission-driven organizations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most.” Under the terms of the agreement, Cancer Research Horizons will license Twist’s Library of Libraries, an expansive collection of synthesized antibody libraries designed based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of antibody drug targets, for a period of five years. Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.